Search

Your search keyword '"Broukou A"' showing total 2 results
Start Over Author "Broukou A" Topic histone deacetylase inhibitors
2 results on '"Broukou A"'

1. Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells.

Author

Aouali N, Broukou A, Bosseler M, Keunen O, Schlesser V, Janji B, Palissot V, Stordeur P, and Berchem G

Subjects
Animals, Cell Survival, Drug Synergism, Female, Inhibitory Concentration 50, Mice, Inbred NOD, Mice, SCID, Multiple Myeloma drug therapy, Multiple Myeloma metabolism, PPAR gamma agonists, Vorinostat, Xenograft Model Antitumor Assays, Antineoplastic Agents pharmacology, Benzamides pharmacology, Epigenesis, Genetic drug effects, Histone Deacetylase Inhibitors pharmacology, Hydroxamic Acids pharmacology, Multiple Myeloma genetics, Pyrimidines pharmacology
Abstract

Epigenetic modifications play a major role in the development of multiple myeloma. We have previously reported that the PPARγ agonist pioglitazone (PIO) enhances, in-vitro, the cytotoxic effect of the Histone deacetylase inhibitor (HDACi), valproic acid (VPA), on multiple myeloma cells. Here, we described the development of a new multiple myeloma mouse model using MOLP8 cells, in order to evaluate the effect of VPA/PIO combination on the progression of myeloma cells, by analyzing the proliferation of bone marrow plasma cells. We showed that VPA/PIO delays the progression of the disease and the invasion of myeloma cells in the bone marrow. Mechanistically, we demonstrated that VPA/PIO increases the cleavage of caspase 3 and PARP, and induces the acetylation of Histone 3 (H3). Furthermore, we provided evidence that PPARγ agonist is able to enhance the action of other HDACi such as Vorinostat or Mocetinostat. Using PPARγ antagonist or siPPARγ, we strongly suggest that, as described during adipogenesis, PIO behaves as an epigenetic regulator by improving the activity of HDACi. This study highlights the therapeutic benefit of PIO/VPA combination, compared to VPA treatment as a single-arm therapy on multiple myeloma and further highlights that such combination may constitute a new promising treatment strategy which should be supported by clinical trials.

Published
2015
Full Text
View/download PDF

2. Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells

Author

Vincent Schlesser, Bassam Janji, Angeliki Broukou, Nassera Aouali, Manon Bosseler, Olivier Keunen, Philippe Stordeur, Guy Berchem, and Valérie Palissot

Subjects
Mocetinostat, medicine.drug_class, Cell Survival, Peroxisome proliferator-activated receptor, lcsh:Medicine, Antineoplastic Agents, Mice, SCID, Pharmacology, Biology, Hydroxamic Acids, Epigenesis, Genetic, chemistry.chemical_compound, Inhibitory Concentration 50, Mice, Inbred NOD, medicine, Cytotoxic T cell, Animals, lcsh:Science, Vorinostat, Multiple myeloma, chemistry.chemical_classification, Multidisciplinary, Histone deacetylase inhibitor, lcsh:R, Drug Synergism, medicine.disease, Xenograft Model Antitumor Assays, Histone Deacetylase Inhibitors, PPAR gamma, medicine.anatomical_structure, Pyrimidines, chemistry, Benzamides, Female, lipids (amino acids, peptides, and proteins), lcsh:Q, Bone marrow, Histone deacetylase, Multiple Myeloma, medicine.drug, Research Article
Abstract

Epigenetic modifications play a major role in the development of multiple myeloma. We have previously reported that the PPARγ agonist pioglitazone (PIO) enhances, in-vitro, the cytotoxic effect of the Histone deacetylase inhibitor (HDACi), valproic acid (VPA), on multiple myeloma cells. Here, we described the development of a new multiple myeloma mouse model using MOLP8 cells, in order to evaluate the effect of VPA/PIO combination on the progression of myeloma cells, by analyzing the proliferation of bone marrow plasma cells. We showed that VPA/PIO delays the progression of the disease and the invasion of myeloma cells in the bone marrow. Mechanistically, we demonstrated that VPA/PIO increases the cleavage of caspase 3 and PARP, and induces the acetylation of Histone 3 (H3). Furthermore, we provided evidence that PPARγ agonist is able to enhance the action of other HDACi such as Vorinostat or Mocetinostat. Using PPARγ antagonist or siPPARγ, we strongly suggest that, as described during adipogenesis, PIO behaves as an epigenetic regulator by improving the activity of HDACi. This study highlights the therapeutic benefit of PIO/VPA combination, compared to VPA treatment as a single-arm therapy on multiple myeloma and further highlights that such combination may constitute a new promising treatment strategy which should be supported by clinical trials.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results